Suppression of systemic inflammation and signs of acute and chronic cholangitis by multi-kinase inhibitor 1-(4-Cl-benzyl)-3-chloro-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione
作者:Halyna Kuznietsova、Iryna Byelinska、Natalia Dziubenko、Oksana Lynchak、Demyd Milokhov、Olga Khilya、Nataliya Finiuk、Olga Klyuchivska、Rostyslav Stoika、Volodymyr Rybalchenko
DOI:10.1007/s11010-021-04144-y
日期:2021.8
An aberrant activity of growth factor receptors followed by excessive cell proliferation plays a significant role in pathogenesis of cholangitis. Therefore, inhibition of these processes could be a fruitful therapeutic strategy. The effects of multi-kinase inhibitor 1-(4-Cl-benzyl)-3-chloro-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione (MI-1) on the hepatic and systemic manifestations of acute and chronic cholangitis in rats were addressed. MI-1 (2.7 mg/kg per day) was applied to male rats that experienced α-naphthylisothiocyanate-induced acute (3 days) or chronic (28 days) cholangitis. Liver autopsy samples, blood serum markers, and leukograms were studied. MI-1 localization in liver cells and its impact on viability of HepG2 (human hepatoma), HL60 (human leukemia), and NIH3T3 (normal murine fibroblasts) cell lines and lymphocytes of human peripheral blood (MTT, DNA fragmentation, DNA comet assays, Propidium Iodide staining) were assessed. Under both acute and chronic cholangitis, MI-1 substantially reduced liver injury, fibrosis, and inflammatory scores (by 46–86%) and normalized blood serum markers and leukograms. Moreover, these effects were preserved after a 28-day recovery period (without any treatment). MI-1 inhibited the HL60, HepG2 cells, and human lymphocytes viability (IC50 0.6, 9.5 and 8.3 µg/ml, respectively), while NIH3T3 cells were resistant to that. Additionally, HepG2 cells and lymphocytes being incubated with MI-1 demonstrated insignificant pro-apoptotic and pro-necrotic changes and DNA single-strand breaks, suggesting that MI-1 effects in liver might be partly caused by its cytotoxic action towards liver cells and lymphocytes. In conclusion, MI-1 attenuated the systemic inflammation and signs of acute and chronic cholangitis partly through cytotoxicity towards cells of hepatic and leukocytic origin.
生长因子受体的异常活性和细胞的过度增殖在胆管炎的发病机制中起着重要作用。因此,抑制这些过程可能是一种富有成效的治疗策略。本研究探讨了多激酶抑制剂 1-(4-Cl-苄基)-3-氯-4-(CF3-苯基氨基)-1H-吡咯-2,5-二酮(MI-1)对急性和慢性胆管炎大鼠肝脏和全身表现的影响。对α-萘基异硫氰酸盐诱发急性(3 天)或慢性(28 天)胆管炎的雄性大鼠施用 MI-1(每天 2.7 毫克/千克)。研究人员对肝脏解剖样本、血清标记物和白细胞图进行了研究。评估了 MI-1 在肝细胞中的定位及其对 HepG2(人肝癌)、HL60(人白血病)和 NIH3T3(正常鼠成纤维细胞)细胞系和人外周血淋巴细胞活力的影响(MTT、DNA 断裂、DNA 彗星试验、碘化丙啶染色)。在急性和慢性胆管炎的情况下,MI-1 都能大幅减少肝损伤、纤维化和炎症评分(减少 46-86%),并使血清标志物和白细胞图谱正常化。此外,这些效果在 28 天的恢复期(无任何治疗)后仍能保持。MI-1 可抑制 HL60、HepG2 细胞和人类淋巴细胞的存活率(IC50 分别为 0.6、9.5 和 8.3 µg/ml),而 NIH3T3 细胞对其具有抗性。此外,用 MI-1 培养的 HepG2 细胞和淋巴细胞表现出不明显的促凋亡和促坏死变化以及 DNA 单链断裂,这表明 MI-1 对肝脏的影响可能部分是由其对肝细胞和淋巴细胞的细胞毒性作用引起的。总之,MI-1减轻全身炎症和急慢性胆管炎症状的部分原因是其对肝细胞和白细胞的细胞毒性作用。